DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

RHHBY·Roche Holding AG

$.
-. (-.%)
After Hours
High
$52.68
Open
$52.21
Market Cap
266.66B
52W High
$337.40
Low
$52.07
P. Close
$52.60
P/E
20.70
52W Low
$291.00
Fwd P/E
16.29
Mean Target
-
Technical Score (1D)
59
BUY
News Sentiment
58
BULLISH
Roche has launched its Liver Disease Panel, a suite of certified algorithms designed to assist in the management of chronic liver disease. This non-invasive panel, including the LiverPRO algorithm, uses routine blood markers and age to detect liver fibrosis, addressing a significant global health need. The development supports patient care from initial risk identification through to liver cancer surveillance, offering a new tool for a condition affecting 1.5 billion people worldwide. In broader market context, potential U.S. drug pricing policies, such as the Most-Favored-Nation policy, could exert pressure on pharmaceutical profits by capping prices paid by government programs. While these policies may affect overall sales volumes and profitability across the industry, some companies, including Roche, are identified as potentially offering continued value to investors. Investors will be watching how these pricing pressures materialize and whether companies can maintain profitability through innovation and market positioning.
Earnings Summary
Roche Holding AG, a global healthcare leader established in 1896 and headquartered in Basel, Switzerland, operates significantly within the pharmaceuticals and diagnostics sectors. The company focuses on developing innovative treatments for oncology, immunology, and neurological disorders, complemented by a robust diagnostics division that aids in disease detection and management. This integrated approach positions Roche strongly within the competitive healthcare industry. Roche's recent financial performance shows a mixed trend. In Q1 2026, the company reported revenue estimates of $15.735 billion, though actual results were not provided. Looking back, the most recent reported quarters indicate a deceleration in revenue growth compared to the prior two periods, though specific figures for EPS and revenue actuals are not available for direct comparison. Historically, Roche has demonstrated a strong revenue growth trajectory year-over-year, driven by its pharmaceutical segment, particularly oncology therapies from Genentech. While specific beat/miss patterns against analyst estimates for EPS and revenue are not detailed in the provided data, the company's pipeline advancements suggest continued potential. Recent news highlights significant developments, including the "All Eyes on DME" campaign by Genentech to raise awareness for diabetic macular edema, potentially boosting demand for related treatments. Furthermore, Roche's experimental multiple sclerosis drug, fenebrutinib, has shown promising relapse reduction in Phase III trials, though safety concerns related to reported deaths warrant close monitoring. Advancements in Gazyva's application for lupus erythematosus and Enspryng's efficacy in MOGAD trials also point to future growth drivers. Investors will be watching for the impact of the DME awareness campaign on sales and any further regulatory developments or clarifications regarding the safety profile of fenebrutinib. Key will be the company's ability to translate pipeline successes into market share and sustained revenue growth, particularly in its core therapeutic areas.

EPS

EstBeatMiss
No data available
QtrEstActual+/−
Q1'26 - - -

Revenue

EstBeatMiss
$15.7B$15.7B$15.7B$15.7B$15.7BQ1'26
QtrEstActual+/−
Q1'26$15.7B - -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RHHBY Stock Snapshot

RHHBY is currently trading at $52.47, giving Roche Holding AG a market cap of 266.66B and a P/E ratio of 20.7. Today's range spans $52.07–$52.68, with shares opening at $52.21 and moving down $0.13 (0.2%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 58/100.

Over the past year RHHBY has traded between $291.00 and $337.40 - the current price is -82.0% off the 52-week low and -84.4% from the high.

The setup for Roche Holding AG (RHHBY) is neither bullish nor bearish - it's patient. Score: 59/100 (HOLD). Sentiment: neutral (58/100). Price: $52.47 (near 52-week lows in $291.00–$337.40). The current P/E ratio stands at 20.7. A large-cap with 266.66B in Healthcare market cap in a neutral technical phase is exactly where position-sizing decisions get made before the next trend emerges.

In neutral phases, large-cap Healthcare names like RHHBY are often where sector rotation debates play out quietly — at 266.66B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 59/100 (HOLD) and neutral sentiment (58/100) at $52.47 (near 52-week lows) describe a stock that is being considered rather than avoided.